Could a lower dose of a transplant drug be better for blood cancer patients?

NCT ID NCT05436418

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with blood cancers who are receiving stem cells from a related donor. Participants will get different doses of cyclophosphamide along with other immune-suppressing drugs, and researchers will track their recovery and side effects for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide
What this could lead to: If successful, this could lead to a safer, more effective way to prevent graft-versus-host disease after stem cell transplants, improving outcomes for blood cancer patients.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so results may not apply to everyone. Lowering the dose might also reduce its effectiveness in preventing graft-versus-host disease or controlling the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia hematopoietic and lymphoid system neoplasm histiocytic and dendritic cell neoplasm Hodgkins lymphoma myelodysplastic syndrome neoplasm of mature T-cells or NK-cells plasma cell myeloma primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANTATION PERIPHERAL BLOOD STEM CELL TRANSPLANTATION

Contacts and locations

Locations

City of Hope
NOT_YET_RECRUITING

Duarte, California, 91010, United States
National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.